ReviewFrontiers in oncology2024

Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.

Ana Costa Cordeiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.